Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMAB NYSE:RDY NASDAQ:SMMT NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$28.60+1.1%$24.38$17.24▼$28.75$18.14B0.931.41 million shs744,899 shsRDYDr. Reddy's Laboratories$14.59-1.9%$14.34$12.26▼$16.19$12.42B0.32744,412 shs571,631 shsSMMTSummit Therapeutics$19.10+1.1%$24.76$15.55▼$36.91$14.03B-1.025.49 million shs3.72 million shsTGTXTG Therapeutics$34.97+8.0%$31.84$21.16▼$46.48$5.14B1.882.06 million shs3.45 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+1.13%+2.18%+16.02%+37.90%+12.03%RDYDr. Reddy's Laboratories-1.82%-0.31%+0.52%-6.52%-7.12%SMMTSummit Therapeutics+1.11%+0.84%-27.10%-8.70%-21.69%TGTXTG Therapeutics+8.03%+10.14%+18.78%-6.25%+41.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$28.60+1.1%$24.38$17.24▼$28.75$18.14B0.931.41 million shs744,899 shsRDYDr. Reddy's Laboratories$14.59-1.9%$14.34$12.26▼$16.19$12.42B0.32744,412 shs571,631 shsSMMTSummit Therapeutics$19.10+1.1%$24.76$15.55▼$36.91$14.03B-1.025.49 million shs3.72 million shsTGTXTG Therapeutics$34.97+8.0%$31.84$21.16▼$46.48$5.14B1.882.06 million shs3.45 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+1.13%+2.18%+16.02%+37.90%+12.03%RDYDr. Reddy's Laboratories-1.82%-0.31%+0.52%-6.52%-7.12%SMMTSummit Therapeutics+1.11%+0.84%-27.10%-8.70%-21.69%TGTXTG Therapeutics+8.03%+10.14%+18.78%-6.25%+41.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.73Moderate Buy$40.0039.86% UpsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9516.18% UpsideSMMTSummit Therapeutics 2.56Moderate Buy$31.8766.84% UpsideTGTXTG Therapeutics 2.80Moderate Buy$48.0037.26% UpsideCurrent Analyst Ratings BreakdownLatest TGTX, GMAB, SMMT, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/23/2025GMABGenmab A/SGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$43.009/17/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$13.009/17/2025TGTXTG TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $55.009/16/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.009/16/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$13.009/16/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/8/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.12B5.88$1.53 per share18.65$8.04 per share3.56RDYDr. Reddy's Laboratories$3.81B3.20$1.01 per share14.40$4.73 per share3.08SMMTSummit Therapeutics$700K20,269.19N/AN/A$0.53 per share36.04TGTXTG Therapeutics$329M16.87$0.13 per share269.83$1.43 per share24.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.9914.3716.071.6537.53%21.03%16.98%11/6/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.1117.796.0116.99%17.25%11.63%11/4/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3794.5134.97N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest TGTX, GMAB, SMMT, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ALatest TGTX, GMAB, SMMT, and RDY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A6.226.20RDYDr. Reddy's Laboratories0.011.891.36SMMTSummit TherapeuticsN/A5.135.13TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%RDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics84.90%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S2,682641.59 million631.71 millionOptionableRDYDr. Reddy's Laboratories27,811834.92 million818.23 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableTGTX, GMAB, SMMT, and RDY HeadlinesRecent News About These CompaniesAnalysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $48.00September 22 at 2:15 AM | americanbankingnews.comWhat is B. Riley's Forecast for TG Therapeutics Q4 Earnings?September 20 at 6:52 AM | marketbeat.comStrs Ohio Makes New Investment in TG Therapeutics, Inc. $TGTXSeptember 20 at 3:03 AM | marketbeat.comB. Riley Has Pessimistic View of TG Therapeutics Q3 EarningsSeptember 20 at 2:13 AM | americanbankingnews.comWhat is B. Riley's Estimate for TG Therapeutics Q3 Earnings?September 19, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comB. Riley Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) StockSeptember 18, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00September 18, 2025 | americanbankingnews.comTG Therapeutics price target raised to $55 from $53 at B. RileySeptember 17, 2025 | msn.comTG Therapeutics, Inc. $TGTX Position Increased by Voya Investment Management LLCSeptember 17, 2025 | marketbeat.comGreat Lakes Advisors LLC Takes $401,000 Position in TG Therapeutics, Inc. $TGTXSeptember 15, 2025 | marketbeat.comIntech Investment Management LLC Grows Stock Holdings in TG Therapeutics, Inc. $TGTXSeptember 15, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Director Sagar Lonial Sells 20,852 SharesSeptember 14, 2025 | marketbeat.comUnited Services Automobile Association Purchases Shares of 8,531 TG Therapeutics, Inc. $TGTXSeptember 14, 2025 | marketbeat.comInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of StockSeptember 13, 2025 | insidertrades.comWoodline Partners LP Takes $21.02 Million Position in TG Therapeutics, Inc. $TGTXSeptember 13, 2025 | marketbeat.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingSeptember 10, 2025 | globenewswire.comTG Therapeutics Begins Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI in Patients with Relapsing Multiple SclerosisSeptember 8, 2025 | quiverquant.comQTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced EnrollmentSeptember 8, 2025 | globenewswire.comCinctive Capital Management LP Purchases Shares of 14,145 TG Therapeutics, Inc. $TGTXSeptember 8, 2025 | marketbeat.comWhy TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback ProgramSeptember 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTGTX, GMAB, SMMT, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$28.60 +0.32 (+1.13%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$28.75 +0.15 (+0.54%) As of 08:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Dr. Reddy's Laboratories NYSE:RDY$14.59 -0.28 (-1.88%) Closing price 09/22/2025 03:59 PM EasternExtended Trading$14.60 +0.01 (+0.03%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$19.10 +0.21 (+1.11%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$19.14 +0.04 (+0.19%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.TG Therapeutics NASDAQ:TGTX$34.97 +2.60 (+8.03%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$34.98 +0.02 (+0.04%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Why Robinhood Stock Is Soaring—and What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
